ArticleJournal of Korean medical science2026
Travel Time to Healthcare and Type 2 Diabetes Mellitus Management in Korea: A Nationwide Retrospective Study.
Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the relationship between average travel time to healthcare facilities and management of type 2 diabetes mellitus (T2DM). In addition, we examined how average travel time and the presence of a usual source of care (USC) interact to influence T2DM management.
methodsWe analyzed National Health Insurance data from 2015 to 2019 for a cohort of 81,588 patients newly diagnosed with T2DM in 2014. Geographic Information System-based road network data were used to calculate travel time. Outcome variables for T2DM management included regular visits, medication adherence, and monitoring tests: hemoglobin testing, lipid panel testing, and fundus examination. Generalized Estimating Equations models were used to assess the effects of travel time on T2DM management.
resultsPatients traveling ≤ 15 minutes to their healthcare facilities had higher rates of regular visits (risk ratio [RR], 1.04; 95% confidence interval [CI], 1.03-1.05), but showed no significant difference in medication adherence (RR, 1.00; 95% CI, 1.00-1.01) relative to patients with longer travel times. The presence of a USC was associated with higher levels of medication adherence (RR, 1.16; 95% CI, 1.15-1.16) and regular visits (RR, 1.38; 95% CI, 1.37-1.40). Patients with both a USC and short travel time had the highest medication adherence and visit rates (RR, 1.14 and 1.42) compared to those without a USC and with longer travel times, reflecting significant interaction effects. Shorter travel time was, however, associated with lower uptake of diabetes monitoring tests. Patients who most frequently visited tertiary or general hospitals had lower regularity of visits and medication adherence but higher rates of diabetes monitoring tests.
conclusionThis study highlights the importance of the combined effect of travel time and the presence of a USC in promoting regular visits to healthcare facilities among T2DM patients, rather than the effect of either factor alone. These findings underscore the need to consider both proximity and continuity of care when planning healthcare access strategies for T2DM management. In addition, measures are needed to promote the implementation of diabetes monitoring tests in clinics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.